ARTICLE | Clinical News
HVJ-E: Phase I/II start
October 10, 2011 7:00 AM UTC
AnGes said this month investigators will begin an open-label, Japanese Phase I/II trial evaluate intratumoral and subcutaneous injections of HVJ-E in 12 CRPC patients. In 2009, AnGes' GenomIdea Inc. ...